276 related articles for article (PubMed ID: 28327826)
1. EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Lasa J; Olivera P
Arq Gastroenterol; 2017; 54(2):167-172. PubMed ID: 28327826
[TBL] [Abstract][Full Text] [Related]
2. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
3. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis.
Baumgart DC; Macdonald JK; Feagan B
Cochrane Database Syst Rev; 2008 Jul; (3):CD007216. PubMed ID: 18646177
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab for induction and maintenance of remission in ulcerative colitis.
Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG
Cochrane Database Syst Rev; 2014 Aug; (8):CD007571. PubMed ID: 25105240
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis.
Ikeya K; Sugimoto K; Kawasaki S; Iida T; Maruyama Y; Watanabe F; Hanai H
Dig Liver Dis; 2015 May; 47(5):365-71. PubMed ID: 25682993
[TBL] [Abstract][Full Text] [Related]
7. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis.
Hoffmann P; Wehling C; Krisam J; Pfeiffenberger J; Belling N; Gauss A
World J Gastroenterol; 2019 Apr; 25(13):1603-1617. PubMed ID: 30983820
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis.
Ogata H; Kato J; Hirai F; Hida N; Matsui T; Matsumoto T; Koyanagi K; Hibi T
Inflamm Bowel Dis; 2012 May; 18(5):803-8. PubMed ID: 21887732
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment.
Boschetti G; Nancey S; Moussata D; Stefanescu C; Roblin X; Chauvenet M; Stroeymeyt K; Bouhnik Y; Flourié B
Dig Liver Dis; 2014 Oct; 46(10):875-80. PubMed ID: 25023007
[TBL] [Abstract][Full Text] [Related]
10. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients.
Schmidt KJ; Herrlinger KR; Emmrich J; Barthel D; Koc H; Lehnert H; Stange EF; Fellermann K; Büning J
Aliment Pharmacol Ther; 2013 Jan; 37(1):129-36. PubMed ID: 23121200
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
[TBL] [Abstract][Full Text] [Related]
13. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients.
Miyoshi J; Matsuoka K; Inoue N; Hisamatsu T; Ichikawa R; Yajima T; Okamoto S; Naganuma M; Sato T; Kanai T; Ogata H; Iwao Y; Hibi T
J Crohns Colitis; 2013 Dec; 7(12):e609-14. PubMed ID: 23680174
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis.
Kawalec P; Mikrut A; Łopuch S
J Gastroenterol Hepatol; 2014 Jun; 29(6):1159-70. PubMed ID: 24955447
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials.
Zhang ZM; Li W; Jiang XL
Gut Liver; 2016 Mar; 10(2):262-74. PubMed ID: 26780088
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis.
Komaki Y; Komaki F; Ido A; Sakuraba A
J Crohns Colitis; 2016 Apr; 10(4):484-94. PubMed ID: 26645641
[TBL] [Abstract][Full Text] [Related]
17. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.
Tsukamoto H; Tanida S; Mizoshita T; Ozeki K; Ebi M; Shimura T; Mori Y; Kataoka H; Kamiya T; Joh T
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):714-8. PubMed ID: 23411870
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review.
Wu B; Tong J; Ran Z
Inflamm Bowel Dis; 2020 Jan; 26(1):24-32. PubMed ID: 30980713
[TBL] [Abstract][Full Text] [Related]
19. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506).
Fellermann K; Ludwig D; Stahl M; David-Walek T; Stange EF
Am J Gastroenterol; 1998 Oct; 93(10):1860-6. PubMed ID: 9772045
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience.
Nuki Y; Esaki M; Asano K; Maehata Y; Umeno J; Moriyama T; Nakamura S; Matsumoto T; Kitazono T
Scand J Gastroenterol; 2016; 51(6):700-5. PubMed ID: 26818468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
